1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Baseline characteristics at time of dAVF diagnosis
All Patients (n = 178) dAVF and CVT (n = 55) dAVF Only (n = 123)
Clinical features      
 Women (n/N) (%) 85/178 (48) 34/55 (62) 51/123 (42)
 Median age (IQR) (yr) 59.0 (49–67) 58.5 (49–68) 60.0 (49–67)
 Asymptomatic 8/178 (4) 0/55 8/123 (7)
 Tinnitus 90/176 (51) 30/54 (56) 60/122 (49)
 Headache 87/177 (49) 27/55 (49) 60/122 (49)
 Ocular symptoms 60/177 (34) 19/55 (35) 41/121 (34)
 Focal neurologic deficit 42/177 (24) 14/55 (13) 28/122 (23)
 Dizziness 28/176 (16) 7/55 (13) 21/121 (17)
 Gait disturbances 16/176 (9) 2/55 (4) 14/121 (12)
 Seizures 10/176 (6) 7/55 (13) 3/121 (3)
 Cranial nerve deficit 14/177 (8) 2/55 (4) 12/122 (10)
 Hearing loss 9/176 (5) 3/54 (6) 6/122 (5)
Thrombotic risk factors (n/N) (%) 
 Traumatic head injury 29/176 (16) 10/54 (19) 19/122 (16)
 Head or neck infection 13/177 (7) 2/54 (4) 11/123 (9)
 Active cancer (treatment <6 months or distant metastases) 5/174 (3) 1/53 (2) 4/121 (3)
 Previous thromboembolism 6/99 (6) 2/29 (7) 4/70 (6)
 OAC use (at time of diagnosis)^{^a} 4/81 (5) 3/31 (10) 1/50 (2)
 Hormone replacement therapy (at time of diagnosis)^{^a} 4/81 (5) 1/31 (3) 3/50 (6)
 Pregnancy or postpartum (<12 weeks)^{^a} 2/83 (2) 1/33 (3) 1/50 (2)
 Obesity (BMI >30 kg/m²) 19/123 (15) 5/41 (12) 14/82 (17)
 Immobility (≥4 days) 1/173 (1) 0/52 1/121 (1)
Note:—OAC indicates oral contraceptive; BMI, body mass index.
↵a Proportions of female patients.